{"id":73921,"date":"2025-10-14T12:32:08","date_gmt":"2025-10-14T12:32:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/73921\/"},"modified":"2025-10-14T12:32:08","modified_gmt":"2025-10-14T12:32:08","slug":"4dmt-to-participate-in-chardans-9th-annual-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/73921\/","title":{"rendered":"4DMT to Participate in Chardan’s 9th Annual Genetic Medicines Conference"},"content":{"rendered":"

EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in panel discussions at Chardan\u2019s 9th Annual Genetic Medicines Conference on October 21st, 2025. Members of the management team will also be available for one-on-one meetings.<\/p>\n

Chardan\u2019s 9th Annual Genetic Medicines Conference<\/p>\n

Panel Title:In Vivo Gene Therapy: Breaking into Competitive Ophthalmic IndicationsPresentation Time:9:30 a.m. ETWebcast Link:Webcast<\/a>\u00a0\u00a0Panel TitleIn Vivo Gene Therapies in the Lung: Treating CF and BeyondPresentation Time:2:00 p.m. ETWebcast Link:Webcast<\/a><\/p>\n

Archived copies of the webcasts will be available for up to one year on the “Investors\u201d section of the 4DMT website at\u00a0https:\/\/ir.4dmoleculartherapeutics.com\/events<\/a>.<\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

About 4DMT \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company\u2019s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company\u2019s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company\u2019s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT.<\/p>\n

All of the Company\u2019s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company\u2019s product candidates for the therapeutic uses for which they are being studied.<\/p>\n

Learn more at www.4DMT.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

Contacts:<\/p>\n

Media:<\/p>\n

Jenn Gordon<\/p>\n

dna Communications<\/p>\n

[email\u00a0protected]<\/a><\/p>\n

Investors:<\/p>\n

Julian Pei<\/p>\n

Head of Investor Relations and Strategic Finance<\/p>\n

[email\u00a0protected]<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a…\n","protected":false},"author":2,"featured_media":73922,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[52488,52490,377,85,2314,46,52489,141,273],"class_list":{"0":"post-73921","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-4dmt","9":"tag-chardan","10":"tag-genetics","11":"tag-il","12":"tag-in","13":"tag-israel","14":"tag-participate","15":"tag-science","16":"tag-to"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/73921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=73921"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/73921\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/73922"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=73921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=73921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=73921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}